alexa Abstract | Synthesis and anticancer activity of some new N'-[(3-Substituted alkyl/aryl)-4- oxo-1,3-thiazolidin-2-ylidene]-4-hydroxybenzohydrazide derivatives

Journal of Chemical and Pharmaceutical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Original Articles Open Access


A novel series of N'-[(3-Substituted alkyl/aryl)-4-oxo-1,3-thiazolidin-2-ylidene]-4-hydroxybenzohydrazide (4.a-4.m) compounds were synthesised. The compounds were tested for its toxicity (in vivo). The cut off LD50 were found ≥ 1000 mg/kg. Anticancer activity of these compounds was performed In vitro by cell proliferation assay using 3- (4,5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT) staining method. Cell lines (A-549), Adeno carcinomic human alveolar basal epithelial cell line is used for screening. The compds, (6.h), (6.i), (6.k), (6.l) and (6.m), showed significant anticancer activity as percent cell lysis <75 to 100. Other compounds also exhibited promising anticancer activity.

To read the full article Peer-reviewed Article PDF image

Author(s): Prashant A Patil Sandeep S Pathare and Kishore P Bhusari


Anticancer activity, Hydroxybenzohydrazide, Thiazolidin, MTT assay, Synthesis and anticancer activity

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version